KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Common Equity: 2009-2025

Historic Common Equity for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Sep 2025 value amounting to $6.1 billion.

  • Biomarin Pharmaceutical's Common Equity rose 11.88% to $6.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 billion, marking a year-over-year increase of 11.88%. This contributed to the annual value of $5.7 billion for FY2024, which is 14.27% up from last year.
  • Biomarin Pharmaceutical's Common Equity amounted to $6.1 billion in Q3 2025, which was up 0.49% from $6.0 billion recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Common Equity registered a high of $6.1 billion during Q3 2025, and its lowest value of $4.2 billion during Q1 2021.
  • In the last 3 years, Biomarin Pharmaceutical's Common Equity had a median value of $5.3 billion in 2024 and averaged $5.3 billion.
  • Data for Biomarin Pharmaceutical's Common Equity shows a peak YoY skyrocketed of 31.05% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Biomarin Pharmaceutical's Common Equity stood at $4.3 billion in 2021, then grew by 7.91% to $4.6 billion in 2022, then climbed by 7.57% to $5.0 billion in 2023, then rose by 14.27% to $5.7 billion in 2024, then increased by 11.88% to $6.1 billion in 2025.
  • Its last three reported values are $6.1 billion in Q3 2025, $6.0 billion for Q2 2025, and $5.8 billion during Q1 2025.